Basic Information
Voraxaze
Regulatory Information
February 12, 2024
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Voraxaze is indicated to reduce toxic plasma methotrexate concentration in adults and children (aged 28 days and older) with delayed methotrexate elimination or at risk of methotrexate toxicity.
Overview Summary
Voraxaze is a medicine used to lower the level of methotrexate (a cancer medicine) in the blood of adults and children older than 28 days whose body is not able to remove methotrexate quickly enough or who are at risk of methotrexate toxicity (when methotrexate is harmful to normal cells and organs in the body). Methotrexate toxicity is rare, and Voraxaze was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 3 February 2003. Voraxaze contains the active substance glucarpidase.